"A new consumer-friendly form ( is now available for making reports to MedWatch, the Food and Drug Administration's (FDA) on-line system for collecting information about serious problems with drugs, medical devices and other FDA-"...
(Generic versions may still be available.)
BIAVAX (rubella and mumps virus vaccine live) II is a sterile lyophilized preparation of the Wistar RA 27/3 strain of live attenuated rubella virus grown in human diploid cell (WI-38) culture; and the Jeryl Lynn (B level) strain of mumps virus grown in cell cultures of chick embryo. The vaccine viruses are the same as those used in the manufacture of MERUVAX* II (Rubella Virus Vaccine Live) and MUMPSVAX* (Mumps Virus Vaccine Live). The two viruses are mixed before being lyophilized.
The reconstituted vaccine is for subcutaneous administration. When reconstituted as directed, the dose for injection is 0.5 mL and contains not less than the equivalent of 1,000 TCID 50 of the U.S. Reference Rubella Virus and 20,000 TCID 50 of the U.S. Reference Mumps Virus. Each dose contains approximately 25 mcg of neomycin. The product contains no preservative. Sorbitol and hydrolized gelatin are added as stabilizers.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Biavax Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.